Former CBER Director Peter Marks Brings Genetic Medicines Street Cred To Lilly

 
• By Jessica Merrill
  
CBER Dir. Peter Marks at Reagan-Udall Foundation for FDA.
Peter Marks admits the FDA was surprised by some efficacy and durability issues in gene therapy - but thinks these will be just a 'bump in the road'. • Source: Shutterstock

More from US FDA

More from Agency Leadership